Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?

Hematol Oncol Clin North Am. 2017 Jun;31(3):441-452. doi: 10.1016/j.hoc.2017.01.004. Epub 2017 Mar 29.

Abstract

The outcome of patients with locally advanced, resectable gastric cancer, or adenocarcinoma of the gastroesophageal junction is poor. In clinical trials, multimodality therapy, such as perioperative chemotherapy, preoperative or postoperative chemoradiation, or adjuvant chemotherapy led to significant increments in survival. Therefore, experts agree that patients with stage II or III disease should be offered a multidisciplinary treatment approach. However, patients are treated somewhat differently in the different regions of the world and survival rates remain far from being satisfactory. Efforts to further improve outcome are highly warranted.

Keywords: Chemotherapy; Gastroesophageal cancer; Locally advanced; Perioperative.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma* / diagnosis
  • Adenocarcinoma* / mortality
  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / therapy
  • Antineoplastic Agents / therapeutic use*
  • Disease-Free Survival
  • Esophageal Neoplasms* / diagnosis
  • Esophageal Neoplasms* / mortality
  • Esophageal Neoplasms* / pathology
  • Esophageal Neoplasms* / therapy
  • Esophagogastric Junction / pathology*
  • Humans
  • Neoplasm Staging
  • Stomach Neoplasms* / diagnosis
  • Stomach Neoplasms* / mortality
  • Stomach Neoplasms* / pathology
  • Stomach Neoplasms* / therapy
  • Survival Rate

Substances

  • Antineoplastic Agents